Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 10, 2007

GenVec to Develop Malaria Vaccine for the U.S. Military

  • GenVec entered into a CRADA with the U.S. Military Malaria Vaccine Program for the development and preclinical testing of a malaria vaccine candidate against Plasmodium vivax (P. vivax). Partners include Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center.

    In addition to the CRADA, GenVec has signed a one-year contract with the DoD to construct and test the adenovector-based vaccine, which carries a novel antigen against P. vivax developed by WRAIR scientists. GenVec and its collaborators will jointly design preclinical studies to evaluate the immunogenicity of the adenovector and WRAIR’s recombinant sub-unit vaccine in various combination prime/boost vaccination strategies.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »